Texas
LATEST FROM BIOSPACE
Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.
Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.
During the past two years, fundraising and investment in biotechnology have reached record levels.
The growth of fibril tips is thought to be the ‘Achilles’ heel’ of the process.
There were a fair number of clinical trial announcements last week. Here’s a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
Research seems to concur that a person who has recovered from severe COVID-19 symptoms might experience cognitive function and memory loss later on.
The United States and other wealthy nations now stand at an important place in their COVID-19 vaccine campaigns. The question largely turns to vaccinating the remainder of the population – namely, those under 12 years.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
PRESS RELEASES